Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase Inhibitor in Patients With Previously Treated Unresectable Solid Tumours

Next Previous
Trial Profile

A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase Inhibitor in Patients With Previously Treated Unresectable Solid Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OMX 0407 (Primary)
  • Indications Carcinoma; Colorectal cancer; Haemangiosarcoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors iOmx Therapeutics

Most Recent Events

  • 30 Apr 2025 Results ( As of 30th of October 2024, n=24 )presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 22 Aug 2024 According to iOmx Therapeutics media release, company focusing on generating efficacy data in the dose expansion segment of the study in patients with advanced kidney cancer and angiosarcoma.
  • 22 Aug 2024 According to iOmx Therapeutics media release, Topline data from the 20-patient Phase Ia dose escalation segment showed that OMX-0407 monotherapy was safe and well-tolerated.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top